Tango Therapeutics has announced the first subject dosing in the open-label, multi-centre TNG456 Phase I/II trial.

Olezarsen is a promising treatment for severe hypertriglyceridemia, familial chylomicronemia syndrome and other dyslipidemia.

Satellos said that following the Phase I data, it will be advancing its DMD small molecule to a Phase II trial.

The US FDA has cleared Grifols' investigational new drug (IND) application to commence a Phase II trial of GRF312 Ophthalmic ...

Merck KGaA said that cohort A met the primary endpoint in the Phase II lupus trial but cohort B failed to meet its primary ...

AnnJi Pharmaceutical has reported encouraging outcomes from its randomised, placebo-controlled Phase I/IIa trial of AJ201.

Member states of the World Health Organization (WHO) have recently agreed on the world's first Pandemic Agreement.

KaliVir Immunotherapeutics has concluded the first cohort in the Phase I/Ib STEALTH-001 trial evaluating VET3-TGI for ...

Zura Bio has launched the Phase II TibuSHIELD trial of tibulizumab for moderate to severe hidradenitis suppurativa (HS).

Queen's Health Sciences (QHS) in Canada has announced the launch of a centralised Clinical Trial Support Unit (CTSU).

The shift toward patient-centric trials is real, but challenges in enrolment and retention persist. Patient-centricity has ...

Viridian Therapeutics’ veligrotug has shown one-year durability in a Phase III trial in patients with active thyroid eye ...